Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids.

MLA

Middelkoop, Mei-An, et al. “Evaluation of Marketing Authorization and Clinical Implementation of Ulipristal Acetate for Uterine Fibroids.” Human Reproduction, vol. 37, no. 5, May 2022, pp. 884–94. EBSCOhost, https://doi.org/10.1093/humrep/deac009.

APA

Middelkoop, M.-A., Lange, M. E. de, Clark, T. J., Mol, B. W. J., Bet, P. M., Huirne, J. A. F., Hehenkamp, W. J. K., & de Lange, M. E. (2022). Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids. Human Reproduction, 37(5), 884–894. https://doi.org/10.1093/humrep/deac009

Chicago

Middelkoop, Mei-An, Maria E de Lange, T Justin Clark, Ben Willem J Mol, Pierre M Bet, Judith A F Huirne, Wouter J K Hehenkamp, and Maria E de Lange. 2022. “Evaluation of Marketing Authorization and Clinical Implementation of Ulipristal Acetate for Uterine Fibroids.” Human Reproduction 37 (5): 884–94. doi:10.1093/humrep/deac009.